NEW YORK, April 14, 2017 /PRNewswire/
-- Harwood Feffer LLP (www.hfesq.com) is investigating
potential claims against the board of directors of Lion
Biotechnologies, Inc. ("Lion" or the "Company") (NASDAQ: LBIO)
concerning whether the board has breached its fiduciary duties to
shareholders.
On April 11, 2017, the Company
disclosed that it had settled claims with the U.S. Securities and
Exchange Commission regarding a stock promotion scheme by its
former Chief Executive Officer, Manish
Singh.
Our investigation concerns whether the Company board of
directors has breached its fiduciary duties to shareholders,
grossly mismanaged the Company, and/or committed abuses of control
in connection with the foregoing.
If you own Lion Biotechnologies shares and wish to discuss this
matter with us, or have any questions concerning your rights and
interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
The law firm responsible for this advertisement is Harwood
Feffer LLP (www.hfesq.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-lion-biotechnologies-inc-300439961.html
SOURCE Harwood Feffer LLP